The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

Summary

The Phase I clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in a population ranging from 6 weeks to 59 years of age. The objective of this study is to evaluate the safety of investigational vaccine in healthy adults and children, as well as its safety tolerability, and immunogenicity in healthy infants. The study will be an open-label observation in adults and children, and a randomized, double-blind, placebo-controlled clinical trial in infants.

Timeline

Start

2024-03-27

Primary completion

2024-12-21

Completion

2025-12-18

Drugs

Indications